Bookmark
Forward
QuickView for Ethchlorvynol (compound)
PubChem
| Name: | Ethchlorvynol |
|---|---|
| PubChem Compound ID: | 3281 |
| Description: | A sedative and hypnotic that has been used in the short-term management of INSOMNIA. Its use has been superseded by other drugs. |
| Molecular formula: | C7H9ClO |
| Molecular weight: | 144.598 g/mol |
DrugBank
Identification
| Name: | Ethchlorvynol |
|---|---|
| Name (isomeric): | DB00189 |
| Drug Type: | small molecule |
| Description: | A sedative and hypnotic that has been used in the short-term management of INSOMNIA. Its use has been superseded by other drugs. |
| Synonyms: |
Ethchlorvinol; Ethclorvynol; Ethochlorvynol; Etchlorvinolo; Ethchlorvinyl; Ethchlorovynol; Aethyl-chlorvynol; Ethychlorvynol
|
| Brand: | Normosan, Serensiloline, Placidil, Roeridorm, Normoson, Placidyl, Alvinol, Serenesil, Nostel, Normonson, Serensil, Serenil, Nromoson, Arvynol |
| Category: | Hypnotics and Sedatives |
| CAS number: | 113-18-8 |
Pharmacology
| Indication: | Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents. |
|---|---|
| Pharmacology: | Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known. |
| Mechanism of Action: |
Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is...
show more » |
| Absorption: | Rapidly absorbed from gastrointestinal tract. |
| Protein binding: | 35-50% |
| Biotransformation: | About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation. |
| Half Life: | Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours. |
| Toxicity: | Symptoms of overdose include thrombocytopenia. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
